カテゴリ： GlobalData, アメリカ, 企業調査

The Wistar Institute：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：The Wistar Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9315
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：54
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
The Wistar Institute (Wistar) is a biomedical research institute that carries out medical research and training. The institute performs research in the areas of cancer, infectious diseases, immunology and vaccine development. It also conducts research on genes, gene expression, and DNA biology; cancer biology; translational research; and virology. Wistar develops vaccines against rotavirus, rabies, and rubella; identification of genes associated with breast, lung, prostate and other cancers; and development of monoclonal antibodies and other research technologies and tools. Wista offers postdoctoral, predoctoral, and high school programs in biomedical research. The institute collaborates with scientific investigators and academic and industry partners. Wistar is headquartered in Philadelphia, Pennsylvania, the US.

The Wistar Institute – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
The Wistar Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
The Wistar Institute, Medical Devices Deals, 2012 to YTD 2018 10
The Wistar Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
The Wistar Institute, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Wistar Institute and Harbour BioMed Enter into Research Agreement 12
Innate Biologics Enters into Research Agreement with Wistar Institute 13
Helen F. Graham Cancer Center & Research Institute Enters into Agreement with Wistar Institute 14
Inovio Pharma Enters into Research Agreement with Wistar Institute 15
PhoreMost Enters into Agreement with Wistar Institute 16
Wistar Institute Into Agreement with Fox Chase Chemical Diversity 17
Licensing Agreements 18
ITUS Enters into Licensing Agreement with Wistar Institute 18
Horizon Discovery Enters into Licensing Agreement with Wistar Institute 19
BioTime Enters Into Licensing Agreement With Wistar Institute For SP100 20
Asset Transactions 21
PepVax Acquires Rights from Wistar Institute 21
The Wistar Institute – Key Competitors 22
The Wistar Institute – Key Employees 23
The Wistar Institute – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Government and Public Interest 25
Sep 27, 2018: Targeting multiple members of a family of tumor antigens with a synthetic DNA vaccine shows promise for cancer immunotherapy 25
Sep 05, 2018: Enhancing the Efficacy of Immune Checkpoint Inhibitor Therapy Using a Novel Treatment Combination 26
Jun 13, 2018: Older Melanoma Patients Have Better Response to Immune Checkpoint Blockade Therapy 27
May 30, 2018: Wistar Receives Grant from the Jayne Koskinas Ted Giovanis Foundation for Health and Policy to Support the Breast Cancer Research Consortium 28
Mar 27, 2018: Repurposing Existing FDA-Approved Inhibitors May Provide New Treatment Approach for Ovarian Cancer 29
Mar 21, 2018: Targeting Telomeres to Overcome Therapy Resistance in Advanced Melanoma 30
Feb 12, 2018: Inovio and The Wistar Institute Receive More Than $4.6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria 31
Jan 29, 2018: Science Center’s QED Program Awards $600,000 to Advance the Commercialization of Three University Technologies Awards Given to New Jersey Institute of Technology, Temple University and The Wistar Institute 32
Jan 18, 2018: The Wistar Institute Awarded More Than $1.4 Million to Create a Malaria Vaccine Through Synthetic DNA-Based Technology 34
Dec 14, 2017: Wistar Scientists Identify Mechanism of Impaired Dendritic Cell Function that Weakens Immune and Therapeutic Response to Cancer 35
Nov 15, 2017: Wistar Science Highlights: New Research In Melanoma And Cancer Immunotherapy 36
Nov 06, 2017: The Wistar Institute Awarded More Than $16.5M in Grants to Fund Cancer & Infectious Disease Research and Training 37
Sep 27, 2017: Melanoma Cells Rewire Their Signaling Pathways to Resist Drug Treatment 39
Sep 19, 2017: Tumor-infiltrating B Lymphocytes Promote Melanoma Progression and Resistance to Therapy 40
Sep 11, 2017: Modulating T-Cell Metabolism Uncovers New Technology for Enhancing Immunotherapy 41
Aug 17, 2017: Wistar Scientists Develop Novel Immunotherapy Technology for Prostate Cancer 42
Jul 24, 2017: New Therapeutic Approach for Difficult-to-Treat Subtype of Ovarian Cancer Identified 43
Jul 13, 2017: Wistar Science Highlights: A More Effective Flu Vaccine Design, New Drug Boosts Antitumor Effects, Awards For Melanoma Research 44
Jul 06, 2017: New Synthetic DNA-Based Strategy Shows Promise Against a Diverse Range of Influenza Viruses 45
Apr 24, 2017: Wistar Scientists Discover New Function for ADAR1 in Protecting Stressed Cells from Apoptotic Death 46
Mar 13, 2017: Wistar Research Teams Awarded More Than $4.7 Million in Funding 47
Mar 03, 2017: Wistar’S Qihong Huang, M.D., Ph.D., Receives $50K Grant From The PA Breast Cancer Coalition For Novel Therapeutic Approach For Metastatic Breast Cancer 48
Feb 23, 2017: Anti-Aging Gene Identified as a Novel Promising Therapeutic Target for Older Melanoma Patients 49
Product News 50
Dec 19, 2017: Novel Combination Therapy Shown to Be Effective in Ovarian 50
Sep 20, 2017: Characterization of a Slowly Proliferating Population of Melanoma Cells with High Metastatic Properties 51
Apr 25, 2018: Targeting Telomerase as a Therapeutic Strategy for Difficult-to-Treat Melanoma 52
Jan 11, 2017: The Wistar Institute and Nation’s Cancer Centers Jointly Endorse Updated HPV Vaccine Recommendations 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
The Wistar Institute, Pharmaceuticals & Healthcare, Key Facts 2
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
The Wistar Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
The Wistar Institute, Deals By Therapy Area, 2012 to YTD 2018 9
The Wistar Institute, Medical Devices Deals, 2012 to YTD 2018 10
The Wistar Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Wistar Institute and Harbour BioMed Enter into Research Agreement 12
Innate Biologics Enters into Research Agreement with Wistar Institute 13
Helen F. Graham Cancer Center & Research Institute Enters into Agreement with Wistar Institute 14
Inovio Pharma Enters into Research Agreement with Wistar Institute 15
PhoreMost Enters into Agreement with Wistar Institute 16
Wistar Institute Into Agreement with Fox Chase Chemical Diversity 17
ITUS Enters into Licensing Agreement with Wistar Institute 18
Horizon Discovery Enters into Licensing Agreement with Wistar Institute 19
BioTime Enters Into Licensing Agreement With Wistar Institute For SP100 20
PepVax Acquires Rights from Wistar Institute 21
The Wistar Institute, Key Competitors 22
The Wistar Institute, Key Employees 23

List of Figures
The Wistar Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
The Wistar Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
The Wistar Institute, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[The Wistar Institute：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Banque Cantonale Vaudoise (Private Banking)：企業の戦略・SWOT・財務情報
    Banque Cantonale Vaudoise (Private Banking) - Strategy, SWOT and Corporate Finance Report Summary Banque Cantonale Vaudoise (Private Banking) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Saudi Kayan Petrochemical Co (2350)：企業の財務・戦略的SWOT分析
    Summary Saudi Kayan Petrochemical Co (Saudi Kayan) is a petrochemical company that manufactures and markets specialty chemicals. The company offers products such as ethanolamines, ethoxylates, phenol, cumene, polycarbonate, ethylene, propylene, polyethylene, monoethanolamine, diethanolamine, trietha …
  • SENER Grupo de Ingenieria SA-エネルギー分野：企業M&A・提携分析
    Summary SENER Grupo de Ingenieria SA (SENER) is a construction company that offers engineering services. The company’s services include marine infrastructures, environmental projects, hydraulic engineering, architecture and urban planning. It offers turnkey solutions and operates projects on space, …
  • Amgen Inc (AMGN)：企業の財務・戦略的SWOT分析
    Amgen Inc (AMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Burnet Institute：製薬・医療：M&Aディール及び事業提携情報
    Summary Burnet Institute is a non-profit and independent organization that improves health of poor and vulnerable communities through research, education and public health. The institute offers solutions to major health issues through development and discovery of novel vaccines, diagnostic tests and …
  • Mayne Pharma Group Ltd (MYX)：企業の財務・戦略的SWOT分析
    Summary Mayne Pharma Group Ltd (Mayne Pharma), formerly HalcyGen Pharmaceuticals Ltd, a subsidiary of Mayne Pharma Group Ltd, is a specialty pharmaceutical company that manufactures and markets branded and generic medicinal products. The company’s products comprise erymax capsules, kapanol capsules, …
  • Altra Industrial Motion Corp (AIMC)：企業の財務・戦略的SWOT分析
    Summary Altra Industrial Motion Corp (Altra Industries), formerly Altra Holdings Inc is an industrial equipment company that designs and manufactures power transmission and motion control products. The company offers products such as electric clutches and brakes, couplings, heavy duty clutches and b …
  • Hyundai Motor Co (005380)-エネルギー分野：企業M&A・提携分析
    Summary Hyundai Motor Company (Hyundai) is a global manufacturer of automobiles, which designs, develops and manufactures passenger and heavy duty automobiles and relevant parts. The company manufactures passenger cars under various brand names such as Centennial, Genesis, Veloster, Azera, Sonata, i …
  • Immunicum AB (IMMU)-製薬・医療分野：企業M&A・提携分析
    Summary Immunicum AB (Immunicum) is a biopharmaceutical company that develops immuno-oncology therapies for the treatment of solid tumors. The company’s products include COMBIG, CD70, SUBCUVAX and adenovirusvector. Its SUBCUVAX is in preclinical trials in combination with the adenovirus vector for t …
  • Anika Therapeutics Inc (ANIK)-製薬・医療分野：企業M&A・提携分析
    Summary Anika Therapeutics Inc (Anika) is a medical technology company which develops, manufactures, and markets therapeutic products for tissue protection, repair and regeneration. It offers solutions for orthobiologics, dermal, ophthalmic, surgical and veterinary applications. Its major products i …
  • Sonivate Medical Inc：医療機器：M&Aディール及び事業提携情報
    Summary Sonivate Medical Inc (Sonivate Medical) is a medical device company that develops and manufactures diagnostic imaging technologies. The company offers dual-plane ultrasound probe, a finger-mounted ultrasound probe that leverages innate human hand eye coordination, which with any ultrasound s …
  • Guizhou Space Appliance Co., Ltd.
    Guizhou Space Appliance Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Guizhou Space Appliance Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Bio-Rad Laboratories Inc (BIO)：企業の財務・戦略的SWOT分析
    Bio-Rad Laboratories Inc (BIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Maximus Inc (MMS)：企業の財務・戦略的SWOT分析
    Maximus Inc (MMS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • CSE Global Ltd (544)：石油・ガス：M&Aディール及び事業提携情報
    Summary CSE Global Limited (CSE) is a technology company offering process control systems and integrated plant communication systems. It’s process control systems offers emergency shutdown systems, process shutdown systems, integrated control & safety systems and fire and gas detection systems, well …
  • Burgan Bank Sak：企業の戦略・SWOT・財務分析
    Burgan Bank Sak - Strategy, SWOT and Corporate Finance Report Summary Burgan Bank Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • ARCA biopharma Inc (ABIO)：製薬・医療：M&Aディール及び事業提携情報
    Summary ARCA Biopharma Inc (ARCA), formerly Nuvelo Inc is a developer of genetically targeted therapies for cardiovascular diseases. The company’s product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment …
  • BCD Travel Services B.V.：戦略・SWOT・企業財務分析
    BCD Travel Services B.V. - Strategy, SWOT and Corporate Finance Report Summary BCD Travel Services B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Endo International plc：企業の戦略・SWOT・財務情報
    Endo International plc - Strategy, SWOT and Corporate Finance Report Summary Endo International plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • The AES Corp：企業の発電所・SWOT分析2018
    The AES Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (execu …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆